The Latest in Psoriatic Arthritis

PEST and BMI predict development of PsA in psoriasis patients

September 16, 2022

Psoriatic Arthritis

Flares increase disease burden in PsA

September 16, 2022

Psoriatic Arthritis

More side effects with methotrexate in PsA vs RA patients

September 16, 2022

Psoriatic Arthritis

PsA: Women experience greater disease burden than men

September 16, 2022

Psoriatic Arthritis

PsA: Women experience greater disease burden than men

September 16, 2022

Psoriatic Arthritis

How useful is CRP as a marker for assessing disease activity in PsA?

September 16, 2022

Psoriatic Arthritis

How useful is CRP as a marker for assessing disease activity in PsA?

September 16, 2022

Psoriatic Arthritis

Rapid and sustained improvement in PsA with ustekinumab

September 16, 2022

Psoriatic Arthritis

Isolated axial PsA and eventual development of peripheral disease

September 16, 2022

Psoriatic Arthritis

Secukinumab delays disease flare in juvenile PsA

September 16, 2022

Psoriatic Arthritis

Rheumatology News

Autoimmune diseases linked to spike in post-MI events

September 15, 2022

Rheumatology News

Sustained response at 2 years reported for newly approved oral psoriasis agent

September 15, 2022

Psoriatic Arthritis

Rheumatology News

FDA approves oral TYK2 inhibitor deucravacitinib for treating psoriasis

September 12, 2022

Psoriatic Arthritis

Rheumatology News

Should patients with PsA or ankylosing spondylitis with axial disease be ‘lumped’ or ‘split’?

September 8, 2022

Commentary: IL-Targeted Therapies and Nail Dystrophy in PsA, September 2022

August 31, 2022

Psoriatic Arthritis